- Home
- ATEX vs VALN Comparison
ATEX vs VALN Comparison
Compare ATEX & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEX
- VALN
- Stock Information
- Founded
- ATEX 1997
- VALN 2012
- Country
- ATEX United States
- VALN France
- Employees
- ATEX N/A
- VALN 713
- Industry
- ATEX Telecommunications Equipment
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATEX Telecommunications
- VALN Health Care
- Exchange
- ATEX Nasdaq
- VALN Nasdaq
- Market Cap
- ATEX 528.1M
- VALN 542.5M
- IPO Year
- ATEX N/A
- VALN 2021
- Fundamental
- Price
- ATEX $25.82
- VALN $6.41
- Analyst Decision
- ATEX Buy
- VALN Strong Buy
- Analyst Count
- ATEX 2
- VALN 3
- Target Price
- ATEX $64.00
- VALN $15.33
- AVG Volume (30 Days)
- ATEX 109.9K
- VALN 80.4K
- Earning Date
- ATEX 06-25-2025
- VALN 05-07-2025
- Dividend Yield
- ATEX N/A
- VALN N/A
- EPS Growth
- ATEX N/A
- VALN N/A
- EPS
- ATEX N/A
- VALN N/A
- Revenue
- ATEX $5,902,000.00
- VALN $201,099,222.00
- Revenue This Year
- ATEX $49.39
- VALN $18.74
- Revenue Next Year
- ATEX $2.84
- VALN $29.26
- P/E Ratio
- ATEX N/A
- VALN N/A
- Revenue Growth
- ATEX 66.77
- VALN 21.64
- 52 Week Low
- ATEX $25.35
- VALN $3.62
- 52 Week High
- ATEX $42.91
- VALN $9.50
- Technical
- Relative Strength Index (RSI)
- ATEX 26.79
- VALN 48.84
- Support Level
- ATEX $27.02
- VALN $6.18
- Resistance Level
- ATEX $29.14
- VALN $6.54
- Average True Range (ATR)
- ATEX 1.11
- VALN 0.19
- MACD
- ATEX -0.03
- VALN 0.02
- Stochastic Oscillator
- ATEX 11.11
- VALN 56.61
About ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.